Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

被引：19

作者：

Beloueche-Babari, M. ^{[1
]}

Jamin, Y. ^{[1
]}

Arunan, V. ^{[1
]}

Walker-Samuel, S. ^{[1
]}

Revill, M. ^{[2
]}

Smith, P. D. ^{[2
]}

Halliday, J. ^{[2
]}

Waterton, J. C. ^{[2
]}

Barjat, H. ^{[2
]}

Workman, P. ^{[3
]}

Leach, M. O. ^{[1
]}

Robinson, S. P. ^{[1
]}

机构：

[1] Inst Canc Res & Royal Marsden NHS Fdn Trust, Div Radiotherapy & Imaging, Canc Res UK & EPSRC Canc Imaging Ctr, Sutton SM2 5PT, Surrey, England

[2] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England

[3] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, Sutton SM2 5NG, Surrey, England

来源：

BRITISH JOURNAL OF CANCER | 2013年 / 109卷 / 06期

基金：

英国工程与自然科学研究理事会;

关键词：

MEK; biomarker; non-invasive imaging; diffusion-weighted MRI; human tumour xenografts; KINASE KINASE-1/2 INHIBITOR; ONCOLOGY DRUG DEVELOPMENT; EARLY CLINICAL-TRIALS; IMAGING BIOMARKERS; ANTITUMOR-ACTIVITY; IMPROVED SURVIVAL; BRAF MUTATIONS; MELANOMA; CANCER; THERAPY;

D O I：

10.1038/bjc.2013.456

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Non-invasive imaging biomarkers underpin the development of molecularly targeted anti-cancer drugs. This study evaluates tumour apparent diffusion coefficient (ADC), measured by diffusion-weighted magnetic resonance imaging (DW-MRI), as a biomarker of response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in human tumour xenografts. Methods: Nude mice bearing human BRAF(V600D) WM266.4 melanoma or BRAF(V600E) Colo205 colon carcinoma xenografts were treated for 4 days with vehicle or selumetinib. DW-MRI was performed before and 2 h after the last dose and excised tumours analysed for levels of phospho-ERK1/2, cleaved caspase 3 (CC3) and necrosis. Results: Selumetinib treatment induced tumour stasis and reduced ERK1/2 phosphorylation in both WM266.4 and Colo205 tumour xenografts. Relative to day 0, mean tumour ADC was unchanged in the control groups but was significantly increased by up to 1.6-fold in selumetinib-treated WM266.4 and Colo205 tumours. Histological analysis revealed a significant increase in necrosis in selumetinib-treated WM266.4 and Colo205 xenografts and CC3 staining in selumetinib-treated Colo205 tumours relative to controls. Conclusion: Changes in ADC following treatment with the MEK1/2 inhibitor selumetinib in responsive human tumour xenografts were concomitant with induction of tumour cell death. ADC may provide a useful non-invasive pharmacodynamic biomarker for early clinical assessment of response to selumetinib and other MEK-ERK1/2 signalling-targeted therapies.

引用

页码：1562 / 1569

页数：8

共 48 条

[21] Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib [J].

Gerstner, Elizabeth R. ;

Chen, Poe-Jou ;

Wen, Patrick Y. ;

Jain, Rakesh K. ;

Batchelor, Tracy T. ;

Sorensen, Gregory .

NEURO-ONCOLOGY, 2010, 12 (05) :466-472

[22] Diffusion magnetic resonance imaging: A biomarker for treatment response in oncology [J].

Hamstra, Daniel A. ;

Rehemtulla, Alnawaz ;

Ross, Brian D. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (26) :4104-4109

[23] Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCN Transgenic Mouse Model of Neuroblastoma [J].

Jamin, Yann ;

Tucker, Elizabeth R. ;

Poon, Evon ;

Popov, Sergey ;

Vaughan, Lynsey ;

Boult, Jessica K. R. ;

Webber, Hannah ;

Hallsworth, Albert ;

Baker, Lauren C. J. ;

Jones, Chris ;

Koh, Dow-Mu ;

Pearson, Andrew D. J. ;

Chesler, Louis ;

Robinson, Simon P. .

RADIOLOGY, 2013, 266 (01) :130-140

[24] Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478 [J].

Jordan, BF ;

Runquist, M ;

Raghunand, N ;

Baker, A ;

Williams, R ;

Kirkpatrick, L ;

Powis, G ;

Gillies, RJ .

NEOPLASIA, 2005, 7 (05) :475-485

[25] Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging [J].

Karroum, Oussama ;

Mignion, Lionel ;

Kengen, Julie ;

Karmani, Linda ;

Leveque, Philippe ;

Danhier, Pierre ;

Magat, Julie ;

Bol, Anne ;

Labar, Daniel ;

Gregoire, Vincent ;

Bouzin, Caroline ;

Feron, Olivier ;

Gallez, Bernard ;

Jordan, Benedicte F. .

CONTRAST MEDIA & MOLECULAR IMAGING, 2013, 8 (03) :274-280

[26] Early Therapy Evaluation of Combined Anti-Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging [J].

Kim, Hyunki ;

Morgan, Desiree E. ;

Buchsbaum, Donald J. ;

Zeng, Huadong ;

Grizzle, William E. ;

Warram, Jason M. ;

Stockard, Cecil R. ;

McNally, Lacey R. ;

Long, Joshua W. ;

Sellers, Jeffrey C. ;

Forero, Andres ;

Zinn, Kurt R. .

CANCER RESEARCH, 2008, 68 (20) :8369-8376

[27] Predicting response of colorectal hepatic metastasis: Value of pretreatment apparent diffusion coefficients [J].

Koh, Dow-Mu ;

Scurr, Erica ;

Collins, David ;

Kanber, Baris ;

Norman, Andrew ;

Leach, Martin O. ;

Husband, Janet E. .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 188 (04) :1001-1008

[28] Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial [J].

Koh, Dow-Mu ;

Blackledge, Matthew ;

Collins, David J. ;

Padhani, Anwar R. ;

Wallace, Toni ;

Wilton, Benjamin ;

Taylor, N. Jane ;

Stirling, J. James ;

Sinha, Rajesh ;

Walicke, Pat ;

Leach, Martin O. ;

Judson, Ian ;

Nathan, Paul .

EUROPEAN RADIOLOGY, 2009, 19 (11) :2728-2738

[29] Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression [J].

Kono, Michihiro ;

Dunn, Ian S. ;

Durda, Paul J. ;

Butera, David ;

Rose, Lenora B. ;

Haggerty, Timothy J. ;

Benson, Elizabeth M. ;

Kurnick, James T. .

MOLECULAR CANCER RESEARCH, 2006, 4 (10) :779-792

[30] Dynamic Imaging of emerging resistance during cancer therapy [J].

Lee, Kuei C. ;

Hall, Daniel E. ;

Hoff, Benjamin A. ;

Moffat, Bradford A. ;

Sharma, Surabhi ;

Chenevert, Thomas L. ;

Meyer, Charles R. ;

Leopold, Wilbur R. ;

Johnson, Timothy D. ;

Mazurchuk, Richard V. ;

Rehemtulla, Alnawaz ;

Ross, Brian D. .

CANCER RESEARCH, 2006, 66 (09) :4687-4692

← 1 2 3 4 5 →